510(k) · Cleared
ClearedOpticath Central Venous Oximetry Probe with Fluidic Seal with/Without Heparin
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Hospira, Inc. · DQE Catheter, Oximeter, Fiber-Optic
Cleared on Jun 26, 2006 as substantially equivalent to K820674 (Oximetrix, Inc., 1982) and 1 other predicate after a 61-day review. Its family tree reaches back 1 generation to 1982.
- Decided
- Jun 26, 2006
- Review
- 61 days
- Class
- Class II
- Product code
- DQE
- Recalls
- None
- Predicates
- 2
Its longest line of descent runs back 1 generation to K820674 (1982). 2 ancestors in all. No later device cites it as a predicate yet.
- Root · 1 generation backK820674 OpticathOximetrix, Inc. · 1982
- This deviceK061159 Opticath Central Venous Oximetry Probe with Fluidic Seal…Hospira, Inc. · 2006
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | K820674 | Opticath | Oximetrix, Inc. | 1982 | — |
| 0 (this device) | K061159 | Opticath Central Venous Oximetry Probe with Fluidic Seal with/Without Heparin | Hospira, Inc. | 2006 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2006 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in DQE? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
What was it cleared against? (2)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K820674 | OpticathSummary page 1…has a lateral flush port for pressure monitoring or for infusion of fluids. The subject device is a modification of the predicate OPTICATH® Oximetry Catheter (K820674). The modifications include: 1) reducing the usable length of the probe and removing the guiding balloon since the probe i… | 1982 |
| * | K053609 | Presep and Pediasat Oximetry Catheters and Vigileo Arterial Pressure Cardiac…Summary page 1…OPTICATH Oximetry CatheterK807 (ICU Medical, Hospira, Inc.) PreSep Central Venous Oximetry K053609 Catheter (Edwards Lifesciences) 6. Proposed Device Description: The OPTICATH® Central Venous… | 2006 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- 1 of the 2 ancestors has a recall of any class.
- 1 other device also cites its predicate K820674.
How does its category compare?
All DQE devicesDQE Catheter, Oximeter, Fiber-Optic: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · DQE
1in 2018
2026 to Oct 25, outlined.
Median 510(k) review, days · DQE
Too few DQE 510(k)s in any year since 2007 to give a median.
Recalls per year · DQE
No recall names DQE since 2007.
Adverse event reports per year · DQE
31in 2025
MAUDE reports naming product code DQE, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 20 |
| 2008 | 0 | — | 0 | 12 |
| 2009 | 1 | — | 0 | 51 |
| 2010 | 0 | — | 0 | 64 |
| 2011 | 1 | — | 0 | 54 |
| 2012 | 0 | — | 0 | 79 |
| 2013 | 0 | — | 0 | 58 |
| 2014 | 1 | — | 0 | 38 |
| 2015 | 0 | — | 0 | 58 |
| 2016 | 1 | — | 0 | 68 |
| 2017 | 0 | — | 0 | 47 |
| 2018 | 1 | — | 0 | 38 |
| 2019 | 0 | — | 0 | 63 |
| 2020 | 0 | — | 0 | 39 |
| 2021 | 0 | — | 0 | 39 |
| 2022 | 0 | — | 0 | 57 |
| 2023 | 0 | — | 0 | 48 |
| 2024 | 0 | — | 0 | 47 |
| 2025 | 0 | — | 0 | 31 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The OPTICATH® Central Venous Oximetry Probe with Fluidic Seal is intended for measuring the oxygen saturation of blood.
The OPTICATH® Central Venous Oximetry Probe with Fluidic Seal is indicated for the continuous in vivo measurement of the oxyhemoglobin saturation of blood in the central venous system (ScvO 2) for monitoring hemodynamic status during metabolic, respiratory, cardiovascular, and/or other physiological system(s) compromise in accordance with hospital protocols or current Clinical Standards of Practice. The probe with fluidic seal is also indicated for pressure monitoring and infusion of fluids
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K061159 · printed Nov 6, 2026
Cite this page
510(k) Report. “K061159: Opticath Central Venous Oximetry Probe with Fluidic Seal with/Without Heparin.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K061159
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026